JP4581994B2 - 生体状態情報処理装置、生体状態情報処理方法、生体状態情報管理システム、プログラム、および、記録媒体 - Google Patents
生体状態情報処理装置、生体状態情報処理方法、生体状態情報管理システム、プログラム、および、記録媒体 Download PDFInfo
- Publication number
- JP4581994B2 JP4581994B2 JP2005502361A JP2005502361A JP4581994B2 JP 4581994 B2 JP4581994 B2 JP 4581994B2 JP 2005502361 A JP2005502361 A JP 2005502361A JP 2005502361 A JP2005502361 A JP 2005502361A JP 4581994 B2 JP4581994 B2 JP 4581994B2
- Authority
- JP
- Japan
- Prior art keywords
- correlation
- blood concentration
- concentration data
- index
- sum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000010365 information processing Effects 0.000 title claims description 123
- 238000003672 processing method Methods 0.000 title claims description 47
- 239000002131 composite material Substances 0.000 claims description 647
- 210000004369 blood Anatomy 0.000 claims description 445
- 239000008280 blood Substances 0.000 claims description 445
- 239000002207 metabolite Substances 0.000 claims description 403
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 286
- 150000001413 amino acids Chemical class 0.000 claims description 272
- 238000000034 method Methods 0.000 claims description 161
- 238000004364 calculation method Methods 0.000 claims description 157
- 230000001575 pathological effect Effects 0.000 claims description 152
- 201000010099 disease Diseases 0.000 claims description 105
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 105
- 230000014509 gene expression Effects 0.000 claims description 100
- 238000004458 analytical method Methods 0.000 claims description 92
- 238000005457 optimization Methods 0.000 claims description 70
- 238000004088 simulation Methods 0.000 claims description 69
- 230000008569 process Effects 0.000 claims description 60
- 238000003860 storage Methods 0.000 claims description 56
- 230000002503 metabolic effect Effects 0.000 claims description 52
- 230000004060 metabolic process Effects 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 9
- 210000004185 liver Anatomy 0.000 claims description 9
- 206010016654 Fibrosis Diseases 0.000 claims description 8
- 230000004761 fibrosis Effects 0.000 claims description 6
- 230000007170 pathology Effects 0.000 claims 1
- 238000012545 processing Methods 0.000 description 106
- 241000700159 Rattus Species 0.000 description 96
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 81
- 238000010586 diagram Methods 0.000 description 80
- 238000004891 communication Methods 0.000 description 54
- 230000005540 biological transmission Effects 0.000 description 52
- 206010012601 diabetes mellitus Diseases 0.000 description 51
- 238000005259 measurement Methods 0.000 description 32
- 238000011282 treatment Methods 0.000 description 28
- 208000005176 Hepatitis C Diseases 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 26
- 239000003814 drug Substances 0.000 description 23
- 230000006870 function Effects 0.000 description 23
- 238000003745 diagnosis Methods 0.000 description 21
- 230000000694 effects Effects 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 13
- 229960003067 cystine Drugs 0.000 description 13
- 102000014150 Interferons Human genes 0.000 description 12
- 108010050904 Interferons Proteins 0.000 description 12
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 12
- 208000008589 Obesity Diseases 0.000 description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 229940079322 interferon Drugs 0.000 description 12
- 235000020824 obesity Nutrition 0.000 description 12
- 230000000875 corresponding effect Effects 0.000 description 11
- 230000008676 import Effects 0.000 description 10
- 239000003550 marker Substances 0.000 description 10
- 230000015654 memory Effects 0.000 description 10
- 238000004590 computer program Methods 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 108010000521 Human Growth Hormone Proteins 0.000 description 8
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 8
- 102000013275 Somatomedins Human genes 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 230000002596 correlated effect Effects 0.000 description 8
- 229960004580 glibenclamide Drugs 0.000 description 8
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 8
- UMFJAHHVKNCGLG-UHFFFAOYSA-N n-Nitrosodimethylamine Chemical compound CN(C)N=O UMFJAHHVKNCGLG-UHFFFAOYSA-N 0.000 description 8
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 8
- 229960000698 nateglinide Drugs 0.000 description 8
- 102000013918 Apolipoproteins E Human genes 0.000 description 7
- 108010025628 Apolipoproteins E Proteins 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- 238000005314 correlation function Methods 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- 230000000704 physical effect Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 6
- 102000002265 Human Growth Hormone Human genes 0.000 description 6
- 239000000854 Human Growth Hormone Substances 0.000 description 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 6
- -1 aromatic amino acid Chemical class 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 238000012790 confirmation Methods 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 235000012631 food intake Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229940026510 theanine Drugs 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
- YPWSLBHSMIKTPR-UHFFFAOYSA-N Cystathionine Natural products OC(=O)C(N)CCSSCC(N)C(O)=O YPWSLBHSMIKTPR-UHFFFAOYSA-N 0.000 description 5
- ILRYLPWNYFXEMH-UHFFFAOYSA-N D-cystathionine Natural products OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 description 5
- ILRYLPWNYFXEMH-WHFBIAKZSA-N L-cystathionine Chemical compound [O-]C(=O)[C@@H]([NH3+])CCSC[C@H]([NH3+])C([O-])=O ILRYLPWNYFXEMH-WHFBIAKZSA-N 0.000 description 5
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 5
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000011813 knockout mouse model Methods 0.000 description 5
- 235000021590 normal diet Nutrition 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 229960000329 ribavirin Drugs 0.000 description 5
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 241000712461 unidentified influenza virus Species 0.000 description 5
- 101100004286 Caenorhabditis elegans best-5 gene Proteins 0.000 description 4
- 206010061818 Disease progression Diseases 0.000 description 4
- 206010019668 Hepatic fibrosis Diseases 0.000 description 4
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 4
- 125000000899 L-alpha-glutamyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 4
- 241000282887 Suidae Species 0.000 description 4
- 238000013528 artificial neural network Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000005750 disease progression Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000003862 health status Effects 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 241001500351 Influenzavirus A Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 230000036765 blood level Effects 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 229960001052 streptozocin Drugs 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- DRCWOKJLSQUJPZ-DZGCQCFKSA-N (4ar,9as)-n-ethyl-1,4,9,9a-tetrahydrofluoren-4a-amine Chemical compound C1C2=CC=CC=C2[C@]2(NCC)[C@H]1CC=CC2 DRCWOKJLSQUJPZ-DZGCQCFKSA-N 0.000 description 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 2
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical group CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 101001008429 Homo sapiens Nucleobindin-2 Proteins 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 description 2
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 2
- 102100027441 Nucleobindin-2 Human genes 0.000 description 2
- 108010026552 Proteome Proteins 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 235000020905 low-protein-diet Nutrition 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- 101100493820 Caenorhabditis elegans best-1 gene Proteins 0.000 description 1
- 101100004280 Caenorhabditis elegans best-2 gene Proteins 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 101000578774 Homo sapiens MAP kinase-activated protein kinase 5 Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 125000000010 L-asparaginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- 125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100028396 MAP kinase-activated protein kinase 5 Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000011676 menaquinone-4 Substances 0.000 description 1
- 238000002705 metabolomic analysis Methods 0.000 description 1
- 230000001431 metabolomic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010295 mobile communication Methods 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical group OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000011824 transgenic rat model Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
- G16B50/20—Heterogeneous data integration
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Theoretical Computer Science (AREA)
- Evolutionary Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Bioethics (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Public Health (AREA)
- Software Systems (AREA)
- Evolutionary Computation (AREA)
- Epidemiology (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Artificial Intelligence (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Veterinary Medicine (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002357042 | 2002-12-09 | ||
| JP2002357042 | 2002-12-09 | ||
| JP2003205589 | 2003-08-01 | ||
| JP2003205589 | 2003-08-01 | ||
| PCT/JP2003/015713 WO2004052191A1 (ja) | 2002-12-09 | 2003-12-09 | 生体状態情報処理装置、生体状態情報処理方法、生体状態情報管理システム、プログラム、および、記録媒体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010158021A Division JP5707757B2 (ja) | 2002-12-09 | 2010-07-12 | 生体状態情報処理装置、生体状態情報処理方法、生体状態情報管理システム、プログラム、記録媒体、および、情報端末装置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2004052191A1 JPWO2004052191A1 (ja) | 2006-04-06 |
| JP4581994B2 true JP4581994B2 (ja) | 2010-11-17 |
Family
ID=32510622
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005502361A Expired - Lifetime JP4581994B2 (ja) | 2002-12-09 | 2003-12-09 | 生体状態情報処理装置、生体状態情報処理方法、生体状態情報管理システム、プログラム、および、記録媒体 |
| JP2010158021A Expired - Lifetime JP5707757B2 (ja) | 2002-12-09 | 2010-07-12 | 生体状態情報処理装置、生体状態情報処理方法、生体状態情報管理システム、プログラム、記録媒体、および、情報端末装置 |
| JP2013152149A Expired - Lifetime JP5971209B2 (ja) | 2002-12-09 | 2013-07-22 | 生体状態判別方法、生体状態判別装置、プログラム、記録媒体、生体状態判別システム、および情報端末装置 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010158021A Expired - Lifetime JP5707757B2 (ja) | 2002-12-09 | 2010-07-12 | 生体状態情報処理装置、生体状態情報処理方法、生体状態情報管理システム、プログラム、記録媒体、および、情報端末装置 |
| JP2013152149A Expired - Lifetime JP5971209B2 (ja) | 2002-12-09 | 2013-07-22 | 生体状態判別方法、生体状態判別装置、プログラム、記録媒体、生体状態判別システム、および情報端末装置 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8234075B2 (enExample) |
| EP (2) | EP2357581A3 (enExample) |
| JP (3) | JP4581994B2 (enExample) |
| KR (1) | KR100686910B1 (enExample) |
| AU (1) | AU2003289263A1 (enExample) |
| CA (2) | CA2508136A1 (enExample) |
| WO (1) | WO2004052191A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010281826A (ja) * | 2002-12-09 | 2010-12-16 | Ajinomoto Co Inc | 生体状態情報処理装置、生体状態情報処理方法、生体状態情報管理システム、プログラム、および、記録媒体 |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006129513A1 (ja) * | 2005-05-30 | 2006-12-07 | Ajinomoto Co., Inc. | 肝疾患評価装置、肝疾患評価方法、肝疾患評価システム、肝疾患評価プログラムおよび記録媒体 |
| WO2006098192A1 (ja) * | 2005-03-16 | 2006-09-21 | Ajinomoto Co., Inc. | 生体状態評価装置、生体状態評価方法、生体状態評価システム、生体状態評価プログラム、評価関数作成装置、評価関数作成方法、評価関数作成プログラムおよび記録媒体 |
| US20070016389A1 (en) * | 2005-06-24 | 2007-01-18 | Cetin Ozgen | Method and system for accelerating and improving the history matching of a reservoir simulation model |
| EP1865431A1 (en) * | 2006-06-06 | 2007-12-12 | Waters GmbH | System for managing and analyzing metabolic pathway data |
| JP5470848B2 (ja) * | 2006-08-04 | 2014-04-16 | 味の素株式会社 | 肺癌の評価方法、肺癌評価装置、肺癌評価方法、肺癌評価システム、肺癌評価プログラム、記録媒体、および、情報通信端末装置 |
| JP5856364B2 (ja) * | 2006-08-04 | 2016-02-09 | 味の素株式会社 | 抑うつ病の評価方法、抑うつ病評価装置、抑うつ病評価方法、抑うつ病評価システム、抑うつ病評価プログラム、記録媒体および端末装置 |
| WO2008015929A1 (fr) | 2006-08-04 | 2008-02-07 | Ajinomoto Co., Inc. | procédé d'évaluation de syndrome métabolique, appareil D'ÉVALUATION DE SYNDROME MÉTABOLIQUE, système D'ÉVALUATION DE SYNDROME MÉTABOLIQUE, programme d'évaluation de syndrome métabolique et support d'enregistrement, et proc& |
| WO2008075662A1 (ja) | 2006-12-21 | 2008-06-26 | Ajinomoto Co., Inc. | 乳癌の評価方法、ならびに乳癌評価装置、乳癌評価方法、乳癌評価システム、乳癌評価プログラムおよび記録媒体 |
| EP2096439A4 (en) * | 2006-12-21 | 2011-01-05 | Ajinomoto Kk | METHOD FOR ASSESSING COLORECTAL CARCINOMA, COLORECTAL CARCINOMA ASSESSMENT DEVICE, METHOD, SYSTEM, PROGRAM AND RECORDING MEDIUM |
| KR101542037B1 (ko) | 2006-12-21 | 2015-08-05 | 아지노모토 가부시키가이샤 | 암 상태의 평가 방법, 및 암 평가 장치, 암 평가 방법, 암 평가 시스템, 암 평가 프로그램 및 기록 매체 |
| EP2124059A4 (en) * | 2007-01-24 | 2010-10-20 | Ajinomoto Kk | METHOD OF EVALUATING IBD, AMINO-SURFACE DATA PROCESSING DEVICE, AMINO-SITE DATA PROCESSING METHOD, AMINO-SURFACE DATA PROCESSING SYSTEM, AMINO-SITE DATA PROCESSING PROGRAM, AND RECORDING MEDIUM |
| JP5016316B2 (ja) * | 2007-01-31 | 2012-09-05 | メディアクロス株式会社 | メタボリックシンドローム血管評価システム |
| EP2172775A4 (en) * | 2007-06-25 | 2010-12-01 | Ajinomoto Kk | METHOD OF EVALUATING VISCERAL GREASE ACCUMULATION |
| WO2009054351A1 (ja) * | 2007-10-25 | 2009-04-30 | Ajinomoto Co., Inc. | 生体状態評価装置、生体状態評価方法、生体状態評価システム、生体状態評価プログラムおよび記録媒体 |
| WO2009054350A1 (ja) | 2007-10-25 | 2009-04-30 | Ajinomoto Co., Inc. | 耐糖能異常の評価方法 |
| KR101361601B1 (ko) * | 2008-03-04 | 2014-02-12 | 아지노모토 가부시키가이샤 | 암종의 평가 방법 |
| CN102057276B (zh) * | 2008-06-20 | 2016-04-06 | 味之素株式会社 | 女性生殖器癌症的评价方法 |
| WO2009154297A1 (ja) | 2008-06-20 | 2009-12-23 | 味の素株式会社 | 前立腺疾患の評価方法 |
| WO2010064413A1 (ja) * | 2008-12-01 | 2010-06-10 | 国立大学法人山口大学 | 薬剤の作用・副作用予測システムとそのプログラム |
| WO2013002381A1 (ja) | 2011-06-30 | 2013-01-03 | 味の素株式会社 | 脂肪性肝疾患の評価方法、脂肪性肝疾患評価装置、脂肪性肝疾患評価方法、脂肪性肝疾患評価プログラム、脂肪性肝疾患評価システム、情報通信端末装置、および脂肪性肝疾患の予防・改善物質の探索方法 |
| WO2013005790A1 (ja) * | 2011-07-07 | 2013-01-10 | 味の素株式会社 | 生体酸化の評価方法、生体酸化評価装置、生体酸化評価方法、生体酸化評価プログラム、生体酸化評価システム、情報通信端末装置、および生体酸化の予防・改善物質の探索方法 |
| CN103082993B (zh) * | 2011-10-31 | 2016-01-20 | 国民技术股份有限公司 | 人体生物信息检测系统及其检测方法 |
| JP6270257B2 (ja) * | 2012-01-31 | 2018-01-31 | 味の素株式会社 | 取得方法、心血管イベント評価装置、心血管イベント評価プログラム、心血管イベント評価システムおよび端末装置 |
| CN110133300B (zh) * | 2012-03-18 | 2022-02-25 | 镜株式会社 | 疾病样品分析装置、分析系统及分析方法 |
| WO2013168550A1 (ja) * | 2012-05-11 | 2013-11-14 | 味の素株式会社 | 癌免疫療法の評価方法、癌免疫療法評価装置、癌免疫療法評価プログラム、癌免疫療法評価システムおよび情報通信端末装置 |
| JP6269502B2 (ja) | 2012-11-27 | 2018-01-31 | 味の素株式会社 | 膵臓癌の評価方法、膵臓癌評価装置、膵臓癌評価方法、膵臓癌評価プログラム、膵臓癌評価システムおよび端末装置 |
| KR102362357B1 (ko) | 2013-04-09 | 2022-02-15 | 아지노모토 가부시키가이샤 | 생활습관병 지표의 평가 방법, 생활습관병 지표 평가 장치, 생활습관병 지표 평가 방법, 생활습관병 지표 평가 프로그램, 생활습관병 지표 평가 시스템, 및 정보통신 단말장치 |
| KR102614827B1 (ko) | 2014-10-08 | 2023-12-19 | 아지노모토 가부시키가이샤 | 평가 방법, 평가 장치, 평가 프로그램, 평가 시스템, 및 단말 장치 |
| JP6886241B2 (ja) * | 2016-01-07 | 2021-06-16 | 味の素株式会社 | 骨格筋面積の評価方法 |
| US10235431B2 (en) | 2016-01-29 | 2019-03-19 | Splunk Inc. | Optimizing index file sizes based on indexed data storage conditions |
| PT3480599T (pt) | 2016-06-30 | 2024-10-18 | Ajinomoto Kk | Método de avaliação da cetose pós-parto |
| WO2018066621A1 (ja) | 2016-10-04 | 2018-04-12 | 味の素株式会社 | 大腸癌の評価方法、評価装置、評価プログラム、評価システム、及び端末装置 |
| KR102427924B1 (ko) * | 2016-10-04 | 2022-08-02 | 아지노모토 가부시키가이샤 | 췌장암의 평가 방법, 평가 장치, 평가 프로그램, 평가 시스템, 및 단말 장치 |
| WO2018101450A1 (ja) * | 2016-12-01 | 2018-06-07 | 味の素株式会社 | 癌モニタリングの方法、算出方法、評価装置、算出装置、評価プログラム、算出プログラム、評価システム、及び端末装置 |
| EP3779453A4 (en) * | 2018-04-10 | 2022-01-05 | Ajinomoto Co., Inc. | METHOD, DEVICE AND PROGRAM FOR EVALUATING THE HEALTH AND / OR GROWTH STATUS OF LIVESTOCK |
| WO2020067386A1 (ja) | 2018-09-26 | 2020-04-02 | 味の素株式会社 | 軽度認知障害の評価方法、算出方法、評価装置、算出装置、評価プログラム、算出プログラム、記録媒体、評価システムおよび端末装置 |
| WO2020242907A1 (en) | 2019-05-24 | 2020-12-03 | National Oilwell Varco. L.P. | Wellsite monitoring system and method |
| US20210225513A1 (en) * | 2020-01-22 | 2021-07-22 | XY.Health Inc. | Method to Create Digital Twins and use the Same for Causal Associations |
| EP4702837A1 (en) | 2023-04-28 | 2026-03-04 | Ajinomoto Co., Inc. | Method for evaluating metabolic disease following calving |
| CN122459686A (zh) | 2023-12-28 | 2026-07-24 | 味之素株式会社 | 分娩后的炎症的评价方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61126472A (ja) | 1984-11-24 | 1986-06-13 | Advance Res & Dev Co Ltd | 診断方法 |
| CA1328018C (en) | 1987-11-13 | 1994-03-22 | Masahiko Kanda | Liver function testing apparatus |
| JPH0620459B2 (ja) * | 1987-11-13 | 1994-03-23 | 住友電気工業株式会社 | 肝機能検査装置 |
| WO1992013273A1 (en) | 1991-01-18 | 1992-08-06 | Esa, Inc. | Method of diagnosing or categorizing disorders from biochemical profiles |
| WO1996012187A1 (en) | 1994-10-13 | 1996-04-25 | Horus Therapeutics, Inc. | Computer assisted methods for diagnosing diseases |
| AU717449B2 (en) * | 1995-07-25 | 2000-03-23 | Horus Therapeutics, Inc. | Computer assisted methods for diagnosing diseases |
| US5687716A (en) | 1995-11-15 | 1997-11-18 | Kaufmann; Peter | Selective differentiating diagnostic process based on broad data bases |
| US6059724A (en) * | 1997-02-14 | 2000-05-09 | Biosignal, Inc. | System for predicting future health |
| US6300136B1 (en) | 1997-09-03 | 2001-10-09 | The Trustees Of The University Of Pennsylvania | Methods for diagnosis and treatment of tumors in humans |
| US20040022827A1 (en) | 1997-09-30 | 2004-02-05 | Chugai Seiyaku Kabusiki Kaisha | Remedy for hepatopathy |
| JPH11190734A (ja) | 1997-12-26 | 1999-07-13 | Wakamoto Pharmaceut Co Ltd | クローン病の検査方法および検査用キット |
| KR20020003384A (ko) | 1999-04-26 | 2002-01-12 | 써로메드, 인크. | 표현형 및 생물학적 마커 동정 시스템 |
| AU1760001A (en) * | 1999-11-10 | 2001-06-06 | Quest Diagnostics Investments Incorporated | Use of computationally derived protein structures of genetic polymorphisms in pharmacogenomics and clinical applications |
| WO2001078652A2 (en) | 2000-04-14 | 2001-10-25 | Metabolon, Inc. | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| CN1242727C (zh) | 2000-04-18 | 2006-02-22 | 大和制衡株式会社 | 内脏脂肪测定装置 |
| WO2002006829A2 (en) | 2000-07-18 | 2002-01-24 | Correlogic Systems, Inc. | A process for discriminating between biological states based on hidden patterns from biological data |
| JP4545899B2 (ja) | 2000-07-31 | 2010-09-15 | キヤノン株式会社 | 加熱装置および画像形成装置 |
| US6631330B1 (en) | 2000-08-21 | 2003-10-07 | Assistance Publique-Hopitaux De Paris (Ap-Hp) | Diagnosis method of inflammatory, fibrotic or cancerous disease using biochemical markers |
| AU2001294644A1 (en) * | 2000-09-19 | 2002-04-02 | The Regents Of The University Of California | Methods for classifying high-dimensional biological data |
| JP4315603B2 (ja) * | 2001-01-26 | 2009-08-19 | 東京瓦斯株式会社 | 炎症性腸疾患診断剤 |
| JP3933882B2 (ja) | 2001-03-30 | 2007-06-20 | 富士通株式会社 | レーダーチャートを表示させるためのプログラムおよびレーダーチャート表示方法 |
| US20040158581A1 (en) * | 2001-05-21 | 2004-08-12 | Max Kotlyar | Method for determination of co-occurences of attributes |
| JP2003159095A (ja) | 2001-07-12 | 2003-06-03 | Takeda Chem Ind Ltd | 結合分子予測方法およびその利用方法 |
| JP2005500543A (ja) * | 2001-08-13 | 2005-01-06 | ビヨンド ジェノミクス， インコーポレイテッド | 生物学的系をプロファイリングするための方法およびシステム |
| US20030077833A1 (en) | 2001-09-07 | 2003-04-24 | Queen's University At Kingston | Diagnositc methods for determining susceptibility to convulsive conditions |
| WO2003083133A1 (en) | 2002-03-29 | 2003-10-09 | Asahi Kasei Pharma Corporation | Method of detecting mild impaired glucose tolerance or insulin hyposecretion |
| JP2004135546A (ja) | 2002-10-16 | 2004-05-13 | Sumitomo Pharmaceut Co Ltd | クローン病の疾患マーカー及びその利用 |
| WO2004038602A1 (en) | 2002-10-24 | 2004-05-06 | Warner-Lambert Company, Llc | Integrated spectral data processing, data mining, and modeling system for use in diverse screening and biomarker discovery applications |
| JP4581994B2 (ja) * | 2002-12-09 | 2010-11-17 | 味の素株式会社 | 生体状態情報処理装置、生体状態情報処理方法、生体状態情報管理システム、プログラム、および、記録媒体 |
| JP2004321179A (ja) | 2003-04-07 | 2004-11-18 | Nitto Boseki Co Ltd | 炎症性腸疾患診断用マーカー遺伝子もしくは蛋白質およびそれを利用した炎症性腸疾患診断方法 |
| US7064104B2 (en) | 2003-06-13 | 2006-06-20 | The Procter & Gamble Company | Methods of managing the symptoms of premenstrual syndrome |
| US20060170928A1 (en) | 2003-12-24 | 2006-08-03 | Vadivel Masilamani | Masila's cancer detector based on optical analysis of body fluids |
| JP4200441B2 (ja) | 2003-08-13 | 2008-12-24 | 財団法人柏戸記念財団 | 臨床検査データの可視化表現シートの作成装置 |
| AU2004267806A1 (en) * | 2003-08-20 | 2005-03-03 | Bg Medicine, Inc. | Methods and systems for profiling biological systems |
| US8346482B2 (en) | 2003-08-22 | 2013-01-01 | Fernandez Dennis S | Integrated biosensor and simulation system for diagnosis and therapy |
| WO2005060608A2 (en) | 2003-12-11 | 2005-07-07 | Correlogic Systems, Inc. | Method of diagnosing biological states through the use of a centralized, adaptive model, and remote sample processing |
| US7433853B2 (en) | 2004-07-12 | 2008-10-07 | Cardiac Pacemakers, Inc. | Expert system for patient medical information analysis |
-
2003
- 2003-12-09 JP JP2005502361A patent/JP4581994B2/ja not_active Expired - Lifetime
- 2003-12-09 CA CA002508136A patent/CA2508136A1/en not_active Abandoned
- 2003-12-09 KR KR1020057010476A patent/KR100686910B1/ko not_active Expired - Lifetime
- 2003-12-09 WO PCT/JP2003/015713 patent/WO2004052191A1/ja not_active Ceased
- 2003-12-09 AU AU2003289263A patent/AU2003289263A1/en not_active Abandoned
- 2003-12-09 EP EP11157821A patent/EP2357581A3/en not_active Withdrawn
- 2003-12-09 EP EP03777384A patent/EP1570779A4/en not_active Withdrawn
- 2003-12-09 CA CA002637250A patent/CA2637250A1/en not_active Abandoned
-
2005
- 2005-06-09 US US11/148,352 patent/US8234075B2/en active Active
-
2010
- 2010-07-12 JP JP2010158021A patent/JP5707757B2/ja not_active Expired - Lifetime
-
2012
- 2012-05-30 US US13/483,359 patent/US20120239366A1/en not_active Abandoned
-
2013
- 2013-07-22 JP JP2013152149A patent/JP5971209B2/ja not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010281826A (ja) * | 2002-12-09 | 2010-12-16 | Ajinomoto Co Inc | 生体状態情報処理装置、生体状態情報処理方法、生体状態情報管理システム、プログラム、および、記録媒体 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2508136A1 (en) | 2004-06-24 |
| KR100686910B1 (ko) | 2007-02-26 |
| JP2010281826A (ja) | 2010-12-16 |
| JPWO2004052191A1 (ja) | 2006-04-06 |
| AU2003289263A1 (en) | 2004-06-30 |
| WO2004052191A1 (ja) | 2004-06-24 |
| CA2637250A1 (en) | 2004-06-24 |
| US20050283347A1 (en) | 2005-12-22 |
| EP1570779A4 (en) | 2008-03-12 |
| JP2013257333A (ja) | 2013-12-26 |
| EP2357581A3 (en) | 2012-09-12 |
| EP2357581A2 (en) | 2011-08-17 |
| US8234075B2 (en) | 2012-07-31 |
| KR20050084227A (ko) | 2005-08-26 |
| EP1570779A1 (en) | 2005-09-07 |
| US20120239366A1 (en) | 2012-09-20 |
| JP5707757B2 (ja) | 2015-04-30 |
| JP5971209B2 (ja) | 2016-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5707757B2 (ja) | 生体状態情報処理装置、生体状態情報処理方法、生体状態情報管理システム、プログラム、記録媒体、および、情報端末装置 | |
| JP7215507B2 (ja) | 取得方法、評価装置、評価プログラムおよび評価システム | |
| JP7291605B2 (ja) | 取得方法、算出方法、糖尿病評価装置、算出装置、糖尿病評価プログラム、算出プログラム、糖尿病評価システム、および端末装置 | |
| Thorpe et al. | Neighborhood socioeconomic environment and risk of type 2 diabetes: associations and mediation through food environment pathways in three independent study samples | |
| CN1748217A (zh) | 增强计算机辅助医疗数据处理系统及方法 | |
| CN1748218A (zh) | 综合医疗知识库界面系统及方法 | |
| Kinney et al. | Identification of chronic obstructive pulmonary disease axes that predict all-cause mortality: the COPDGene study | |
| WO2006098192A1 (ja) | 生体状態評価装置、生体状態評価方法、生体状態評価システム、生体状態評価プログラム、評価関数作成装置、評価関数作成方法、評価関数作成プログラムおよび記録媒体 | |
| JP2016029398A (ja) | 内臓脂肪面積の評価方法、内臓脂肪面積評価装置、内臓脂肪面積評価方法、内臓脂肪面積評価プログラム、記録媒体、内臓脂肪面積評価システム、及び端末装置 | |
| US20100280809A1 (en) | Biological state-evaluating apparatus, biological state-evaluating method, biological state-evaluating system, biological state-evaluating program and recording medium | |
| WO2008015929A1 (fr) | procédé d'évaluation de syndrome métabolique, appareil D'ÉVALUATION DE SYNDROME MÉTABOLIQUE, système D'ÉVALUATION DE SYNDROME MÉTABOLIQUE, programme d'évaluation de syndrome métabolique et support d'enregistrement, et proc& | |
| US20140113378A1 (en) | Method of evaluating fatty liver related disease, fatty liver related disease-evaluating apparatus, fatty liver related disease-evaluating method, fatty liver related disease-evaluating program product, fatty liver related disease-evaluating system, information communication terminal apparatus, and method of searching for prophylactic/ameliorating substance for fatty liver related disease | |
| Yang et al. | TIGA: target illumination GWAS analytics | |
| Zhu et al. | LMCD-OR: a large-scale, multilevel categorized diagnostic dataset for oral radiography | |
| JPWO2009054350A1 (ja) | 耐糖能異常の評価方法、耐糖能異常評価装置、耐糖能異常評価方法、耐糖能異常評価システム、耐糖能異常評価プログラムおよび記録媒体、ならびに耐糖能異常の予防・改善物質の探索方法 | |
| CN100502763C (zh) | 生物体状态信息处理装置和其方法、以及生物体状态信息管理系统 | |
| Elwell‐Cuddy et al. | The construction and application of a population physiologically based pharmacokinetic model for methadone in Beagles and Greyhounds | |
| Thorpe et al. | We examined whether relative availability of fast-food restaurants and super-markets mediates the association between worse neighborhood socioeconomic conditions and risk of developing type 2 diabetes (T2D). | |
| Unasa et al. | Identifying data‐fields for a gastrointestinal cancer clinical quality and safety registry: a systematic literature review | |
| Kudachi et al. | Sociopsychological and biochemical determinants of health and disease in executive health check-up | |
| JP6886241B2 (ja) | 骨格筋面積の評価方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060711 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090602 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090729 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100511 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100712 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100803 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100816 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4581994 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130910 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130910 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |